Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 5: 8-Day randomized clinical trial in Japan


Authored by  A R Tricker, S Kanada, K Takada*, C Martin Leroy, D Lindner, MK Schorp*, R Dempsey

Published in Regulatory Toxicology and Pharmacology    
* This author is not affiliated with PMI.

Abstract

A randomized, controlled, open-label, parallel-group, single-center study to determine biomarkers of exposure to twelve selected harmful and potentially harmful constituents (HPHCs) in cigarette smoke and urinary excretion of mutagenic material in 128 male and female Japanese subjects smoking Marlboro cigarettes (6 mg tar, 0.5 mg nicotine, and 7.0 mg CO) at baseline. Subjects were randomized to continue smoking Marlboro cigarettes, or switch to the Electrically Heated Cigarette Smoking System (EHCSS) and smoke either the EHCSS-K6 (5 mg tar, 0.3 mg nicotine, and 0.6 mg CO) or the EHCSS-K3 (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO) cigarette, or switch to smoking Lark One cigarettes (1 mg tar, 0.1 mg nicotine, and 2.0 mg CO), or to no-smoking. The mean decreases from baseline to Day 8 were statistically significant (p ⩽ 0.05) for all cigarette smoke HPHC including CO (the primary objective) and excretion of mutagenic material in the EHCSS-K6 (range: −14.6% to −75.6%) and EHCSS-K3 (range: −9.8% to −73.0%) groups. Statistically significant reductions (all p ⩽ 0.05) in exposure to ten cigarette smoke HPHC (range: −5.9% to −34.6%), but not urinary mutagenicity, were observed in the Lark One group. The largest mean reductions in exposure to HPHC (all p ⩽ 0.01 level) occurred in the no-smoking group (range: −13.7% to −97.6%).